Menlo Therapeutics Inc (MNLO) Stock Price & Overview

NASDAQ:MNLO

1.35
-0.03 (-2.17%)
At close: Sep 4, 2020
1.38
+0.03 (+2.22%)
After Hours: 9/4/2020, 8:18:36 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

The current stock price of MNLO is 1.35 null. Today MNLO is down by -2.17%. In the past month the price decreased by -16.41%. In the past year, price decreased by -71.7%.

MNLO Key Statistics

52-Week Range1 - 7.48
Current MNLO stock price positioned within its 52-week range.
1-Month Range1.3 - 1.71
Current MNLO stock price positioned within its 1-month range.
Market Cap
226.383M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-3.75
Dividend Yield
N/A

MNLO Stock Performance

Today
-2.17%
1 Week
-8.78%
1 Month
-16.41%
3 Months
-34.47%
Longer-term
6 Months -67.47%
1 Year -71.70%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

MNLO Stock Chart

Menlo Therapeutics Inc / MNLO Daily stock chart

MNLO Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to MNLO. When comparing the yearly performance of all stocks, MNLO is a bad performer in the overall market: 96.96% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
MNLO Full Technical Analysis Report

MNLO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MNLO. Both the profitability and financial health of MNLO have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MNLO Full Fundamental Analysis Report

MNLO Earnings

Next Earnings DateN/A
Last Earnings DateN/A
MNLO Earnings History

MNLO Forecast & Estimates


Analysts
Analysts100
Price TargetN/A
EPS Next Y25.24%
Revenue Next YearN/A
MNLO Forecast & Estimates

MNLO Financial Highlights

Over the last trailing twelve months MNLO reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS decreased by -32.98% compared to the year before.


Income Statements
Revenue(TTM)13.44M
Net Income(TTM)-246.03M
Industry RankSector Rank
PM (TTM) -1830.82%
ROA -188.03%
ROE N/A
Debt/Equity 0.46
Chartmill High Growth Momentum
EPS Q2Q%-75.36%
Sales Q2Q%N/A
EPS 1Y (TTM)-32.98%
Revenue 1Y (TTM)4262.99%
MNLO financials

MNLO Ownership

Ownership
Inst Owners50.07%
Shares167.69M
Float141.46M
Ins Owners3.21%
Short Float %N/A
Short RatioN/A
MNLO Ownership

About MNLO

Company Profile

Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California.

Company Info

Menlo Therapeutics Inc

520 U.S. HIGHWAY 22 SUITE 204

BRIDGEWATER NJ 08807

CEO: Steven Basta

Phone: 800-775-7936

Menlo Therapeutics Inc / MNLO FAQ

What does Menlo Therapeutics Inc do?

Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California.


What is the current price of MNLO stock?

The current stock price of MNLO is 1.35 null. The price decreased by -2.17% in the last trading session.


What is the dividend status of Menlo Therapeutics Inc?

MNLO does not pay a dividend.


What is the ChartMill rating of Menlo Therapeutics Inc stock?

MNLO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is Menlo Therapeutics Inc worth?

Menlo Therapeutics Inc (MNLO) has a market capitalization of 226.38M null. This makes MNLO a Micro Cap stock.